Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROZAC WEEKLY vs BRISDELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
90 mg orally once weekly
8 mg orally once daily, taken at bedtime.
Fluoxetine: 4-6 days after single dose, 4-6 days (extended to 7-9 days with chronic dosing due to autoinhibition of CYP2D6); norfluoxetine: 9-31 days. Steady state achieved after 2-4 weeks.
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Hepatic via CYP2D6, CYP2C9, and CYP3A4; active metabolite norfluoxetine.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Renal excretion of metabolites (primarily fluoxetine glucuronide and norfluoxetine glucuronide) accounts for approximately 80% of elimination; fecal excretion accounts for approximately 15%.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Approximately 94.5% bound to plasma proteins, including albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
12-43 L/kg (average ~25 L/kg). Large Vd indicates extensive tissue distribution, including brain and fat; contributes to prolonged elimination.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
Oral: ~90% (not significantly affected by food). Weekly formulation: same bioavailability as daily dosing.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
No dose adjustment required for GFR ≥15 m L/min; insufficient data for GFR <15 m L/min, use with caution.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
Child-Pugh Class A: no adjustment; Class B: initiate at 20 mg/day (immediate-release) or use alternative; Class C: contraindicated or use with extreme caution.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate with 20 mg/day (immediate-release) and increase cautiously; monitor for hyponatremia and SIADH; PROZAC WEEKLY not recommended due to limited data.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Mania/hypomania,Seizures,Altered platelet function,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Concomitant use with MAOIs,Concomitant use with pimozide or thioridazine,Known hypersensitivity to fluoxetine
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
Grapefruit and grapefruit juice may increase fluoxetine levels; avoid large amounts. No specific dietary restrictions, but take with food if GI upset occurs.
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
First trimester: Crosses placenta; risk of major congenital malformations based on some studies (e.g., cardiovascular defects approx. 1.8% vs 1% baseline). Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN) approx. 0.3% vs 0.1% baseline. Late trimester: Neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) in ~30% exposed neonates.
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Fluoxetine and norfluoxetine are excreted in breast milk. Infant serum concentrations are typically low (<10% maternal weight-adjusted dose). M/P ratio for fluoxetine ~0.8; norfluoxetine ~0.2. Cases of adverse effects (fussiness, poor feeding) are rare. Benefits may outweigh risks in moderate-severe depression.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
No dose adjustment required based on PK studies in pregnancy. However, due to increased volume of distribution and clearance late in pregnancy, some patients may require a dose increase to maintain efficacy; monitor clinical response and adjust dose as needed.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
Fluoxetine has a long half-life (4-6 days; active metabolite norfluoxetine 4-16 days) allowing weekly dosing, but requires daily loading for 13 weeks before switching to weekly. Monitor for serotonin syndrome if co-prescribed with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms despite long half-life.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
Take once weekly on the same day, typically 90 mg capsule. Do not crush or chew.,May take 4-8 weeks for full therapeutic effect.,Common side effects include nausea, insomnia, drowsiness, sweating, and sexual dysfunction.,Avoid alcohol as it may worsen side effects.,Contact doctor if rash, suicidal thoughts, or serotonin syndrome symptoms occur.,Do not stop abruptly; withdrawal effects possible.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROZAC WEEKLY vs BRISDELLE, answered by our medical review team.
PROZAC WEEKLY is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.. BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROZAC WEEKLY and BRISDELLE depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROZAC WEEKLY is: 90 mg orally once weekly. The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROZAC WEEKLY and BRISDELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROZAC WEEKLY is classified as Category C. First trimester: Crosses placenta; risk of major congenital malformations based on some studies (e.g., cardiovascular defects approx. 1.8% vs 1% baseline). Third trimester: Risk of. BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.